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Mast cells generate and release histamine during anaphylactic reactions, and there is pharmacological evidence
that histamine regulates this process via speciﬁc receptors. Therefore, we examined human leukemic (HMC-1) and
normal skin mast cells for the expression of all four currently known histamine receptors. Both cell types
expressed H2 and H4 receptors at mRNA and protein levels, whereas H3 receptor speciﬁc mRNA and receptor
protein was undetectable. Similarly, immunohistochemistry of cutaneous tissue showed an absence of H3 receptor
in these cells. Despite transcription of mRNA, H1 receptor protein was only moderately expressed in HMC-1 cells
and was virtually absent in skin mast cells. Furthermore, only H1, H2, and H4 receptors were detectable by Western
blot analysis of HMC-1 cells. Radiolabeled histamine binding was strongly inhibited only by H2 (ranitidine)- and
H3/H4 (FUB 108)-speciﬁc antagonists. Histamine-induced increase of cAMP was inhibited by the H2 receptor
antagonist famotidine, whereas induction of IP3 was not observed, making signaling via the H1 receptor unlikely.
These data show that human mast cells constitutively express primarily H2 and H4 receptors and that H2 receptors
are functionally linked to cellular processes. They provide new insights into the mechanisms that govern auto- and
paracrine histamine-induced mast cell functions.
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Histamine is a multifunctional, ubiquitously distributed
biogenic amine that is stored abundantly in and is rapidly
released from tissue mast cells and blood basophils,
inducing vasodilatation, vascular permeability, and smooth
muscle contraction in target organs of anaphylactic reac-
tions (Jurkiewicz, 1998). Although H1 receptors have been
extensively studied for their effects on allergic reactions
(Hill, 1990), H2 receptors are best known for their function in
gastric acid secretion and in immunomodulation. Besides
the well-known H1 and H2 histamine receptors, two
additional types of histamine receptors have been de-
scribed by molecular cloning of cDNAs encoding G protein
coupled receptors (Gantz et al, 1991; Lovenberg et al, 1999;
Nakamura et al, 2000; Oda et al, 2000). In the 1980s, the H3
receptor was identified as a pre-synaptic heteroreceptor
that is primarily expressed in neurons of the central and
peripheral nervous system where it mediates inhibition of
neurotransmitter release, including histamine release, with a
concomitant decrease of cAMP (Hill, 1990).
The most recently described H4 receptor is more widely
distributed, especially in organs associated with the
immune system (Liu et al, 2000; Morse et al, 2001). Its
abundant expression in cells associated with allergic
reactions, such as eosinophils and T lymphocytes, is of
particular interest (Morse et al, 2001). Data regarding the
type of histamine receptor expressed by mast cells in
different organs and species are variable and in part even
contradictory (Masini et al, 1982; Wescott et al, 1982; Alm
et al, 1984). This also holds for recent pharmacological
studies using human leukemic mast cells (HMC-1 cells)
or RBL cells where H2 and/or H1 receptors were found
to modulate cytokine secretion (Lippert et al, 1995; Hide
et al, 1997; Lippert et al, 2000). H3 receptors were ini-
tially found on rat peritoneal and cutaneous (Ohkubo et al,
1994; Bissonnette, 1996) as well as on human adenoidal
mast cells. (Bent et al, 1991) However, according to more
recent data, they seem to be restricted to the central
nervous system (Rozniecki et al, 1999). Expression of
the H4 receptor has so far been described at the mRNA
level with commercially available probes from cultured
bone marrow-derived mast cells (Morse et al, 2001), and
very recently also indirectly in receptor-deficient mice
(Hofstra et al, 2003). In a preliminary report, we have also
reported its presence at protein level in human skin mast
cells.1
Abbreviations: FACS, flow cytometric analysis; FITC, fluorescein
isothiocyanate; H receptors, histamine receptors; HMC-1 cells,
human leukemic mast cells; PBS, phosphate-buffered saline; PE,
phycoerythrin
1Expression of histamine receptor types 1, 2, and 4 but not type
3, on human mast cells. Lippert U, Artuc M, Gru¨tzkau A, Haase I,
Blaschke V, Zachmann K, Neumann Ch. and Henz B.M. Arch
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In addition to its effects in allergic responses, there is
increasing evidence for numerous other functions of
histamine, such as inhibition of mediator secretion and
involvement in cell growth and adhesion (Jurkiewicz, 1998;
Cuss, 1999). Furthermore, recent studies have described
the expression of functional histamine receptors in human T
cells and dendritic cells, emphasizing the potential immu-
nomodulatory effects of this molecule (Jutel et al, 2001;
Gutzmer et al, 2002; Idzko et al, 2002).
In order to clarify the presence of histamine receptors in
human mast cells, we examined the expression of all four
currently known receptor subtypes in the human mast cell
line HMC-1 and in isolated skin mast cells. Furthermore, we
included an investigation of mast cells localized within the
tissue by immunohistochemical staining. Using specific
H1, H2, and H3/H4 antagonists, functional activities of the
histamine receptors were explored. Besides the clear
demonstration of a functional H2 receptor, the demonstra-
tion of a constitutively strong H4 receptor protein expres-
sion in human mast cells is intriguing in light of its supposed
role in allergic and immunological processes.
Results
Demonstration of histamine receptor expression by
PCR Initially, we examined whether mast cells express
mRNA for all four currently known histamine receptors.
Using RT-PCR analysis, constitutive H1, H2, and H4
receptor expression was detectable in immature HMC-1
cells as well as in skin mast cells (Fig 1A, B). In contrast, the
H3 receptor was undetectable by RT-PCR in both cell types,
although it could be demonstrated in human brain tissue
(Fig 1B). As reported before (Liu et al, 2000; Morse et al,
2001), the H4 receptor was not detected in brain tissue,
underlining the specificity of the PCR products (Fig 1B).
Furthermore, we compared the expression level of the
different histamine receptors in HMC-1 and isolated human
skin mast cells at RNA level as a possible first indication of
their distribution in these cell types. b-Actin served as an
internal standard. As demonstrated in Fig 2C, expression of
H2 and H4 receptor RNA exceed that for the H1 receptor in
both cell types. Interestingly, the major difference in RNA
expression level between both cell types was observed for
the H4 receptor type, which was clearly expressed more
strongly in skin mast cells.
Protein expression of histamine receptors in the HMC-1
cell line as well as in isolated human skin mast cells by
ﬂow cytometric analysis (FACS)-analysis In a next step,
we tried to examine the expression and distribution of
histamine receptor protein in HMC-1 cells and isolated
human skin mast cells. On flow cytometry, almost 90% of
HMC-1 cells exhibited binding of the H2 receptor antibody,
which could be blocked to about 80% on pre-treatment
with the corresponding control peptide (Fig 2A). H1 and H4
receptors were detected in 43% and 49% of HMC-1 cells,
respectively, and this binding was also suppressed by the
corresponding control peptides, as shown in Fig 2A. In
agreement with our PCR data, no binding was noted with
the H3 receptor antibody. As positive control for H1
expression, the histiocytic lymphoma cell line U937 (Davio
et al, 1995) was studied and showed 22% binding, with a
94% inhibition by the control peptide. Human erythrocytes
served as negative controls and, as expected, showed no
Figure1
Studies of H1 and H2 receptor mRNA expression in human mast
cells by RT-PCR. (A) Shows H1 (lanes 1 and 3) and H2 (lanes 2 and 4)
receptor expression by RT-PCR in HMC-1 cells (lanes 1 and 2) and
cutaneous mast cells (lanes 3 and 4). (B) Investigation of H3 and H4
receptor mRNA in HMC-1 cells and human skin mast cells. Neither
HMC-1 cells (lane 1) nor human skin mast cells (lane 3) express the H3
receptor mRNA. The H3 receptor, however, was clearly detected in
brain tissue, which served as positive control, (lane 5). In contrast, H4
receptor expression was found in HMC-1 cells (lane 2) as well as in skin
mast cells (lane 4) whereas it remained undetectable in the brain tissue
(lane 6). (C) Comparison between the mRNA expression of histamine
receptors in HMC-1 cells and human dermal mast cells (HDMC). The
values were normalized by using b-actin and analyzed with the help of
an image analyzer software. The bars represent the means of three
independent experiments, including the standard error.
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binding for any of the four types of histamine receptors
(data not shown).
In human skin mast cells, no H3 receptor and no signi-
ficant expression of H1 receptor was seen on flow cyto-
metry although, in the case the H1 receptor, its expression
at mRNA level was observed (Fig 2B). In contrast, and as in
HMC-1 cells, a high percentage of H2 receptor-positive skin
mast cells was however found (Fig 2B). Interestingly, a
strong constitutive expression of the H4 receptor protein
(about 50%) was detected in skin mast cells as well (Fig 2B).
Demonstration of mast cell histamine receptors in
situ In order to validate the findings on isolated skin mast
cells with cells localized within their tissue environment, we
performed double immunofluorescence staining with the
well-established mast cell marker tryptase and the specific
histamine receptor antibodies.
As can be seen in Fig 3A–C, the H1 receptor protein was
hardly detectable on mast cells whereas almost all mast
cells expressed the H2 receptor protein (Fig 3D–F). In
contrast, no H3 receptor-positive mast cells were detected,
although some non-specific binding was noted in the skin
tissue (Fig 3G–I), underlining our results obtained with
HMC-1 and isolated skin mast cells. As expected from the
data obtained so far by PCR and FACS analysis, the
majority of skin mast cells also expressed the H4 receptor
protein (Fig 3J–L).
Taken together, these findings support the concept that
also within human tissue, the H2 and H4 receptors represent
the main pool of histamine receptors in mast cells.
Determination of histamine receptors protein size by
western blot In order to determine the protein size of
histamine receptors in human mast cells and at the same
time to provide evidence for the quality of the antibodies
used in this study, HMC-1 cells were chosen as a model
since these cells express marked amounts of the H1
receptor protein and since it is very difficult to isolate
sufficient skin mast cells for these experiments. As shown in
Fig 4, expression of two bands for the H1 receptor could be
demonstrated (Fig 4A, lane 1). The band at 60 kDa is of the
expected size, and the smaller one (40 kDa) corresponds
most likely to a proteolytic product, as previously described
in other cells by Ruat et al (1988). Both bands disappeared
after pre-incubation of the antibody with its control peptide
(Fig 4A, lane 2). For the H2 receptor, six bands of 87, 59, 49,
48.5, 37.5, and 30.5 kDa were detected (Fig 4A, lane 3), with
the five latter disappearing after pre-incubation with the
control peptide. Since the largest band (87 kDa) could not
be displaced by the control antibody, this band must be
viewed as being non-specific (Fig 4A, lane 4).
As predicted, no binding was found for the H3 receptor
(Fig 4B, lane 1, antibody alone and lane 2, antibody and
control peptide). In contrast, two bands were detected for
the H4 receptor (90 and 78 kDa) (Fig 4B, lane 3), and both
could be displaced by the control peptide (Fig 4B, lane 4).
These data confirm our findings of histamine receptor
protein expression obtained by FACS analysis.
Histamine binding and its displacement As a next step,
we examined whether mast cell histamine receptors can
indeed bind their histamine ligand, using two different sets
of binding experiments. Initially, we used fluorescence
labeled histamine and FACS. Baseline binding of fluores-
cence labeled histamine to its receptors on HMC-1 cells
showed a concentration-dependent histamine binding of
maximally 30% (Fig 5).
In the second, more classical, set of experiments, [3
H]thymidine labeled histamine was used, together with
specific histamine receptor antagonists in order to deter-
mine histamine binding to specific types of receptors.
Unlabelled histamine inhibited the binding of 3H-histamine
dihydrochloride to HMC-1 cells by about 70% (Fig 6). Non-
specific binding in the presence of 10 mM histamine was
less than 25%. The IC50 and Ki values were 0.838 and 0.7
nM, respectively. Binding was inhibited by about 50% using
either the H2 receptor antagonist ranitidine or the H3
and H4 receptor antagonist FUB 108. In comparison, the
inhibition of histamine binding to the H1 antagonist was
significantly lower.
Functional aspects of histamine receptors A final set of
experiments was addressed at the question of functional
activity of the H1 and H2 receptors. Since histamine binding
to its H2 receptor was marked, and since an increase of
Figure 2
(A) Protein expression and distribution of histamine receptors on
HMC-1 cells by flow cytometry. Statistical analysis from four to six
independent experiments with HMC-1 cells are shown, using specific
H1–H4 histamine receptor antibodies (HR). In addition, the specificity
of the binding was proved by its inhibition after pre-incubation with
the corresponding control peptides (CP). (B) Presence of histamine
receptor protein on human skin mast cells by flow cytometry. Isolated
human skin mast cells were stained with histamine receptor antibodies
(HR) and, in corresponding experiments, also with the antibody and the
control peptide (CP). The columns show the mean data from six to nine
independent experiments.
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intracellular cAMP has been described in association with
H2 receptor ligand interaction (Hill et al, 1990), this effect
was studied as evidence for functionality of this histamine
receptor subtype on HMC-1 cells. As expected, histamine
caused a concentration-dependent increase in cAMP which
was, however, moderate compared with choleratoxin
(positive control) (Fig 7). An almost complete abrogation of
this response was noted on pre-incubation of the cells
with the H2 antagonist famotidine. In contrast, the potent
H1 antagonist desloratadine caused an enhancement of
cAMP-levels that was most pronounced at the highest
doses tested (Fig 7).
Although minor binding of histamine to the H1 receptor
was observed, activation of HMC-1 cells via this receptor
was also studied with regard to the generation of the IP3
response, which represents a typical signaling event for this
receptor in numerous tissues and cell types (Hill et al, 1990).
Histamine at varying concentrations, however, failed to
induce this effect (not shown).
Discussion
The present data provide evidence for the expression of H2
and H4 receptors on HMC-1, on isolated human skin mast
cells and in addition on skin mast cells located within
peripheral human tissue. These receptors seem to account
for most of the histamine binding on human mast cells since
distinct binding was observed on flow cytometry and with
displacement studies using radioactive histamine and
specific receptor antagonists. Against the background of
the well documented differences between murine and
Figure 3
Demonstration of histamine receptor
protein in human tissue mast cells
by confocal laser microscopy. Human
skin sections were stained for the different
histamine receptor subtypes (red) (shown
in A, D, G, J) and for the mast cell marker
tryptase (green) (shown in B, E, H, K).
Cells stained yellow on double staining in
the overlay of both markers (C, F, I, L) are
mast cells that are positive for the
respectively stained H receptor. Note that
only few cells stained for the H1 receptor
(C), whereas nearly all mast cells ex-
pressed the H2 receptor (F). The H3
receptor was undetectable in human
tissue mast cells (I), but the H4 receptor
(L) was again expressed in almost all mast
cells.
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human mast cells, the present data seem of major
importance in view of the applicability of findings in mice
on mast cell function in human disease.
When interpreting the present results, it is important to
keep in mind that H3 and H4 receptors exhibit 40%
homology and are functionally related (Liu et al, 2000;
Morse et al, 2001). H3 inhibitors also bind to the H4
receptor, as noted in preliminary studies for the H3
antagonist FUB 181 that was used here (Stark et al,
1998). In view of the lack of the H3 receptor on skin mast
cells, the histamine displacement noted with FUB 181
strongly suggests the presence of H4 receptors on mast
cells. This assumption was confirmed by the demonstration
of H4 receptor protein expression on HMC-1 and skin mast
cells. Our findings, using western blot analysis and flow
cytometry, and above all the reactivity of the H4 receptor-
specific antibody with mast cells in cutaneous tissue,
confirm and extend the recent data of Morse et al who
demonstrated H4 mRNA using commercially available
cDNA of human mast cells cultured from bone marrow
precursors. The cross-reactivity of H3 antagonists with H4
receptors also offers an explanation for previous data on H3
receptor expression on peripheral mast cells (Bissonnette
et al, 1996) and is in line with recent animal studies that failed
to show expression of H3 receptors on peripherally located
mast cells (Nemmar et al, 1999; Rozniecki et al, 1999).
In functional studies, we were able to demonstrate a
histamine-induced increase of cAMP, which was inhibited
by pre-incubation with an H2 antagonist. These findings
suggest that histamine regulates its own secretion also
in HMC-1 cells, as shown before with H2 antagonists
in association with an intracellular increase of cAMP for
human lung mast cells (Lichtenstein et al, 1973). A similar
Figure 4
Investigation of histamine receptor protein size in HMC-1 cells by
western blot analysis. (A) Shows the expression of the H1 and H2
receptor. For the H1 receptor to bands were detected (lane 1) that
disappeared by pre-incubation of the antibody with the corresponding
peptide (lane 2). Lanes 3 and 4 represent the expression of the H2
receptor (lane 3: antibody alone; lane 4: antibody and control peptide).
Since the 87 kDa band was not inhibited by the corresponding control
peptide, it has to be viewed as unspecific. (B) Detection of the H4
receptor (lane 3) that disappears after pre-incubation with the control
peptide (lane 4). As expected, no expression of the H3 receptor type
was found neither for the antibody alone (lane 1) nor for antibody plus
control peptide (lane 2).
Figure5
Binding of fluorescence-labeled histamine (Bodipy FL histamine)
to HMC-1 cells. Cells were incubated for 60 min at 41C with various
concentrations of fluorescence labeled histamine in the presence or
absence of 1 mM unlabeled histamine. At least 104 cells were analyzed
by an Epics XL flow cytometer.
Figure6
Competition for specific 3H-histamine binding in HMC-1 cells. In
this case, different histamine receptor antagonists also were included in
the study. Data show means  SD of three independent experiments.
The curves were calculated from the computed parameters using
Prism2.
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situation may also apply to secretion of mediators different
from histamine, as recently demonstrated for TNF-a, IL-3,
and IL-8 (Lippert et al, 2000).
The data showing that pre-incubation with an H1
antagonist caused an increase of histamine-induced cAMP
seem surprising at first sight, but they probably indicate a
competitive antagonism between H1 and H2 receptors on
the same cells, as proposed before for other cell types
(Palacios et al, 1978). Overall, H1 receptor expression on
human skin mast cells seems less distinct. Although the
expression of this receptor appears convincing on the basis
of our PCR, western blot and FACS data in HMC-1 cells, the
inhibition of histamine binding on HMC-1 cells by the H1
antagonist is only moderate and may explain why a rise in
IP3 was not noted. In cutaneous mast cells, however, there
was only a very weak expression of the H1 receptor,
indicating that this receptor may be of less importance in
mature or normal mast cells, as holds at least for mast cells
in the skin.
Taken together, functional H2 receptors are expressed
by mast cells where they may exert immunomodulatory
effects, in analogy to findings with lymphocytes and
monocytes (Elenkov et al, 1998; Jutel et al, 2001).
In addition, isolated human mast cells as well as tissue
mast cells also showed a strong constitutive expression of
the H4 receptor protein. This finding is of great interest in
view of the suggested participation of the H4 receptor in
allergic reactions. Although the regulatory function of H4
receptors is not well understood until now, first data indicate
that these receptors may be involved in inhibitory mecha-
nisms, as described before for the closely related H3
receptor (Liu et al, 2000; Morse et al, 2001). On the other
hand, recent reports describe H4 receptor involvement in
migration of murine mast cells, CD4þ T cells, and of
eosinophil granulocytes (Gantner et al, 2002; O’Reilly et al,
2002; Hofstra et al, 2003).
Taken together, H4 receptors might act, together with H2
receptors, in the downregulation of allergic reactions, but
they may also facilitate these reactions by the attraction of
potent allergic effector cells. In view of the currently avail-
able limited and in part even contradictory data regarding
the biological function of H4 receptors, the beneficial or
enhancing roles of these molecules in allergic processes
need to be further elucidated. On the basis of the informa-
tion available so far, one may however expect that new
agents targeted at H4 receptors will soon be developed
providing novel therapeutic regimens for the modulation of
allergic diseases.
Materials and Methods
Cells Human leukemic mast cells (HMC-1, from H. J. Butterfield,
Minneapolis, Minnesota) were cultured as described (Butterfield
et al, 1988). Skin mast cells were isolated from human foreskin
and purified by positive sorting using the monoclonal anti-c-
Kit antibody YB5B8 (kindly provided by L. Ashman, Adelaide,
Australia) and a secondary magnetic microbead-coupled antibody
(Miltenyi Biotec, Bergisch Gladbach, Germany), as previously
detailed (Gru¨tzkau et al, 2000). Cells used for RT-PCR were
495% c-Kit positive on flow cytometry with a phycoerythrin (PE)-
conjugated anti-c-Kit antibody (Coulter Immunotech, Hamburg,
Germany). Histiocytic lymphoma cells (U937, purchased from the
ATCC, Rockville, Maryland, number CRL 1593) was cultured in
RPMI 1640 medium supplemented with 10% FCS. Human
erythrocytes were isolated from whole blood of healthy blood
donors using gradient centrifugation (Prietro et al, 2001) (purity of
99.5%, viability 499%).
Skin specimens were obtained during surgical breast reduc-
tions, with informed consent. Human brain tissue (hypothalmus)
was from the tissue bank of the Neuropathology Department of the
Charite´, Berlin, Germany.
Reagents Histamine dihydrochloride (Sigma, Deisenhofen, Ger-
many) was dissolved at 1 mM in an aqueous stock solution. The
following histamine antagonists were studied with the stock
solutions indicated: H1 antagonists: cetirizine, 102 M (UCB,
Brussels, Belgium) and diphenhydramine hydrochloride, 1 M (ICN,
Eschwege, Germany); desloratadine, 102 M in DMSO (Essex
Pharma, Munich, Germany); H2 antagonists: ranitidine, 1 M (ICN),
famotidine, 102 M in DMSO (Fluka, Deisenhofen, Germany); the
H3/H4 antagonist FUB 181 (Stark et al, 1998) at 102 M in DMSO
(from W. Schunack, Institute of Pharmacology, Free University,
Berlin, Germany).
For flow cytometry and western blot, commercially available
H2, H3, and H4 receptor antibodies were used (all from Alpha
Diagnostic International, San Antonio, Texas). Since no specific
binding with a commercially available H1 receptor antibody was
detected, we produced and affinity purified an H1 receptor
antibody in rabbits, using a keyhole limpet hemocyanin coupled
peptide synthesized on the basis of the sequence of the human H1
receptor (C-N-E-N-F-K-K-T-F-K-R-I-L-H) (Schneider et al, 1983),
corresponding to the H1 receptor located at the 471–485 C-
terminal intracellular domain (Hill, 1990).
RT-PCR analysis RNA was extracted according to the instruc-
tions of the manufacturer (RNeasy, Qiagen, Hilden, Germany) and
reverse transcribed, as reported before (Lippert et al, 1998).
Oligonucleotide primer sequences for H receptors were designed
(MWG Biotech, Ebersberg, Germany) according to the following
sequences published in Genbank, with their accession numbers
given in square brackets: H1 receptor [Z34897], H2 receptor
[M64799], H3 [AB045369], and H4 [AB04370]. PCR products were
subjected to gel electrophoresis and detected by gel analysis
software (Herolab, Wiesloch, Germany). Negative controls with
water instead of cDNA were always included. PCR conditions were
as follows: HIS1-F: ACC-ATC-CAA-AAC-CCC-CAA-GG; HIS1-R:
TCT-TGA-ATG-CGA-GCG-GAG-CC, 373 bp, 2 min 951C, 36 cycles
of 45 s 951C, 45 s 591C, 1 min 721C. HIS2-F: GAC-TCT-ACC-GCA-
TGC-AAG, HIS2-R: GCC-AGT-GGG-TCC-ATG-AC, 336 bp, 2 min
Figure 7
cAMP measurements in HMC-1 cells after treatment with hista-
mine and pre-incubation with an H1 or an H2 antagonist. Cells were
pre-incubated with buffer, desloratadine or famotidine (both at 10 mM)
for 30 min and then stimulated with histamine at 105–108 M. The
value obtained with cells kept in buffer alone was set at 100%, and
choleratoxin was used as positive control. Data represent means  SD
of three independent experiments.
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951C, 38 cycles of 45 s 951C, 45 s 591C, 1 min 721C. HIS3-F: CGG-
CTG-TCA-ACC-CTG-TCC-TCT-ACC, HIS3-R: CCC-AGC-CTC-CAG-
TCC-AGC-CAG-TGA, 334 bp, 2 min 951C, 35 cycles of 45 s
951C, 45 s 651C, 1 min 721C. HIS4-F: GGT-ACA-TCC-TTG-CCA-
TCA-CAT-CAT, HIS4-R: ACT-TGG-CTA-ATC-TCC-TGG-CTC-TAA,
396 bp, 2 min 951C, 35 cycles of 45 s 951C, 45 s 591C, 1 min 721C.
All reactions were terminated by a final elongation step of 10 min at
721C. The PCR products were identified by cycle sequencing,
using the ABI PRISM 310 Genetic Analyzer (Applied Biosystemsd
GmbH, Weiterstadt, Germany).
Quantitative PCR Expression levels of different histamine recep-
tor cDNAs in HMC-1 and skin mast cells were compared by semi-
quantitative PCR. For this purpose, cDNA levels were first
normalized using b-actin as an internal standard. PCR conditions
for b-actin were as follows: b-actin-F: TC TTG TTT TCT GCG and
b-actin-R: CCT TCC TGG GCA TGG AGT CCT 400 bp 5 min 941C,
23 cycle of 1 min 941C, 1 min 581C, 1 min 721C. PCR was
terminated by a final elongation step of 10 min at 721C. Expression
levels of histamine receptors were analyzed by image analyzer
software (UVP Inc, Cambridge, UK).
Flow cytometry Protein expression of histamine receptors was
studied using specific polyclonal rabbit antibodies against the H1,
H2, H3, and H4 receptors and a PE-conjugated F(ab0)2 fragment of
goat anti-rabbit IgG (Biosource, Solingen, Germany) as secondary
antibody. After pre-incubation with human AB serum (Behringwerke
AG, Marburg, Germany) (30 min, 41C) to block non-specific binding,
cells were fixed with 4% paraformaldehyde (Merck, Darmstadt,
Germany), permeabilized with 0.025% saponin (Sigma) and
analyzed by flow cytometry (PAS-III, Partec, Mu¨nster, Germany),
as described (Gru¨tzkau et al, 1997). In some experiments, cells were
pre-incubated with a 10-fold excess of the respective control
peptides (Alpha Diagnostic International) for 1 h min at 41C.
Double immunoﬂuorescence staining of skin sections for
confocal laser microscopy Skin biopsies were fixed in acetone
for 24 h, followed by an incubation in methyl benzoate (30 min) and
in xylene (45 min) under negative pressure, and 3 mm sections were
cut from paraffin embedded tissue. Prior to staining, endogenous
peroxidase was blocked with hydrogen peroxide (0.3%). Non-
specific binding of the antibodies was inhibited by incubation with
TNB buffer (Nen Life Science Products, Boston, Massachusetts)
according to the manufactor’s instructions. Subsequently, the
sections were washed and incubated with the primary antibodies
against H1, H2, H3, and H4 receptors (all diluted 1:50) overnight at
41C. In further steps, slides were treated with peroxidase labelled
goat anti rabbit/goat anti mouse immunoglobulins (DAKO, Hamurg,
Germany), washed and incubated with biotinylated thyramide (1:50
in amplification diluent, Nen Life Science Products). Reactive sites
were detected with indocarbocyanine (Cy3)-conjugated streptavi-
dine (1:1000 in phosphate-buffered saline (PBS), Dianova, Ham-
burg, Germany, 60 min). Slides were washed thoroughly in PBS,
and the second step primary antibody mAb human mast cell
tryptase (diluted 1:300 in PBS, clone AA1, DAKO) was added for
60 min. Subsequently, after washing, Cy5-conjugated goat anti-
mouse immunoglobulins (1:500 in PBS, Dianova) were applied for
60 min. Omission of first or second step antibody and both
antibodies served as negative controls to prove successful
blocking of additional binding sites of the first step primary
antibody and unspecific cellular antigens.
Analysis of dual-color fluorescence signals was digitally
performed with confocal laser microscopy on a Leica TCS NT
laser scanning microscope (Heidelberg, Germany) with 400-fold
magnification.
Immunoblot HMC-1 cells were resuspended in homogenization
buffer (280 mM sucrose, 50 mM TRIS, 1 mM EDTA, ph 7.4
containing protease inhibitors) and homogenized using a ball
cracker. A post-nuclear supernatant was generated by centrifuga-
tion for 15 min at 400  g. Membranes were sedimented using
aTLA100.3 rotor (30 min, 400.000  g) (Beckmann, Fullerton,
California). SDS-PAGE was done on a 10% acrylamide gel, with
50 mg of protein sample per slot and a low range molecular weight
standard (Bio-Rad Laboratories GmbH, Mu¨nchen, Germany). The
protein was transferred to nitrocellulose membranes by electro-
blotting and stained with the anti-H1 (diluted 1:250), -H2, -H3, and
-H4 receptor antibodies (diluted 1:50). As secondary antibody, a
goat anti-rabbit–HRP (horse radish peroxidase) labeled antibody
(diluted 1:1500, Dianova), was used and stained with chlornaphthol
(Merck), as described before (Brand et al, 1991).
Receptor binding studies Initially, binding studies were per-
formed by flow cytometry, as described (Lippert et al, 1998), using
a commercially available fluorescence labeled histamine (Bodipy
FL histamine; Molecular Probes, Leiden, Netherlands). HMC-1
cells were incubated (60 min, 41C) with increasing reagent
concentrations in the presence of 1 mM unlabeled histamine and
analyzed with an Epics XL flow cytometer (Coulter, excitation
wavelength 488 nm, emission wavelength 525 nm). The percent-
age of Bodipy FL histamine binding was calculated as follows: %
histamine Bodipy FL binding¼ (MFI1MFI2)/MFI2  100 (MFI1¼
mean fluorescence intensity in the absence, MFI2¼ the same in
the presence of 1 mM unlabeled histamine).
HMC-1 cells (2  106 per well) were also incubated at 41C with
1 nM 3H-histamine (Amersham Pharma Biotech Europe, Freiburg,
Germany) and increasing concentrations of competing ligand
(unlabeled histamine, desloratadine, ranitidine, FUB 181) in binding
buffer (50 mM Tris/HCl, pH 7.4; 100 mM NaCl, 5 mM MgCl2, 0.25%
bovine serum albumin). Unbound radioactivity was removed by
washing cells on glass fiber filters with ice-cold PBS. Radioactivity
of the filters was counted in a liquid scintillation counter
(Beckmann). Data were analyzed with the non-linear curve-fitting
program Prism2.
cAMP and IP3 assay For assessment of intracellular cAMP, HMC-
1 cells were diluted in 500 mL serum-free basal Iscove’s containing
0.1 mM 3-isobutyl-1-methylxanthine (IBMX) (Calbiochem-Nova-
biochem, Bad Soden, Germany). For stimulation in the presence of
H1 or H2 antagonists, cells were pre-incubated with desloratadine
or famotidine (10 mM) for 30 min at 371C, followed by incubation
with histamine (0.01–10 mM) for another 30 min at 371C. Sub-
sequently, cells were suspended in lysis-buffer, and aliquots were
assayed for cAMP using a specific EIA-kit (Amersham Pharmacia
Biotech). Cells stimulated with choleratoxin (1 nM) (Calbiochem-
Novabiochem) served as positive control.
Histamine-induced effects on generation of inositol 1,4,5-
trisphosphate (IP3) were measured in HMC-1 cells, as reported
before (Haase et al, 1996). Briefly, cells labeled with 5 mCi per mL or
20 mCi per mL 3H-inositol for 24 h were stimulated for 20 s to 30
min and then lysed in 10% perchloric acid. The supernatant was
neutralized using KOH and analyzed by HPLC.
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